• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Ovid Therapeutics Inc.

    5/15/26 4:21:48 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OVID alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Ovid Therapeutics Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)




    690469101

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    690469101


    1Names of Reporting Persons

    Point72 Asset Management, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,903,943.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,903,943.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,903,943.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.3 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  Includes 583,333 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.


    SCHEDULE 13G

    CUSIP Number(s):
    690469101


    1Names of Reporting Persons

    Point72 Capital Advisors, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,903,943.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,903,943.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,903,943.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.3 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Includes 583,333 shares of Common Stock issuable upon exercise of warrants.


    SCHEDULE 13G

    CUSIP Number(s):
    690469101


    1Names of Reporting Persons

    Steven A. Cohen
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,903,943.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,903,943.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,903,943.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.3 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Includes 583,333 shares of Common Stock issuable upon exercise of warrants.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Ovid Therapeutics Inc.
    (b)Address of issuer's principal executive offices:

    441 Ninth Avenue, 14th Floor, New York, NY 10001
    Item 2. 
    (a)Name of person filing:

    This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.001 per share ("Common Stock"), of Ovid Therapeutics Inc. ( the "Issuer") held by (and shares of Common Stock underlying the warrants held by) an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the shares of Common Stock held by (and shares of Common Stock underlying the warrants held by) an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the shares of Common Stock beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Cubist Systematic Strategies, LLC is a relying adviser on the Form ADV of Point72 Asset Management and acts as a sub-advisor with respect to a portion of the Common Stock reported herein.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
    (c)Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    690469101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no shares of Common Stock. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the shares of Common Stock reported herein. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 151,028,955 shares of Common Stock outstanding, which is the sum of (i) 131,874,634 shares of Common Stock outstanding as of March 16, 2026, as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC") on March 18, 2026, and (ii) 19,154,321 shares of Common Stock issued in the private placement entered into on March 17, 2026, as described in the Issuer's Current Report on Form 8-K filed with the SEC on March 18, 2026, and assumes the exercise of the warrants reported herein.
    (b)Percent of class:

    1.3%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.

     (ii) Shared power to vote or to direct the vote:

    The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 2(a).
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Point72 Asset Management, L.P.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:05/15/2026
     
    Point72 Capital Advisors, Inc.
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:05/15/2026
     
    Steven A. Cohen
     
    Signature:/s/ Jason M. Colombo
    Name/Title:Jason M. Colombo, Authorized Person
    Date:05/15/2026
    Get the next $OVID alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OVID

    DatePrice TargetRatingAnalyst
    12/11/2025$3.00Buy
    Roth Capital
    11/17/2025Outperform
    Leerink Partners
    10/9/2025$7.00Outperform
    Oppenheimer
    8/8/2025$3.00Buy
    B. Riley Securities
    6/18/2024Outperform → Perform
    Oppenheimer
    4/30/2024$9.00Buy
    B. Riley Securities
    4/29/2024$9.00Buy
    H.C. Wainwright
    4/5/2024$8.00Outperform
    Wedbush
    More analyst ratings

    $OVID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on Ovid Therapeutics with a new price target

    Roth Capital initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $3.00

    12/11/25 9:12:49 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Ovid Therapeutics

    Leerink Partners initiated coverage of Ovid Therapeutics with a rating of Outperform

    11/17/25 9:41:02 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Ovid Therapeutics with a new price target

    Oppenheimer initiated coverage of Ovid Therapeutics with a rating of Outperform and set a new price target of $7.00

    10/9/25 8:28:36 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    SEC Filings

    View All

    Ovid Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

    6/3/26 7:03:09 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Ovid Therapeutics Inc.

    SCHEDULE 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    5/15/26 4:21:48 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Ovid Therapeutics Inc.

    SCHEDULE 13G - Ovid Therapeutics Inc. (0001636651) (Subject)

    5/15/26 11:57:24 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Alexander Margaret A. bought $4,971 worth of shares (6,810 units at $0.73), increasing direct ownership by 24% to 34,935 units (SEC Form 4)

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    1/29/25 9:18:08 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Levin Jeremy M bought $50,364 worth of shares (18,248 units at $2.76), increasing direct ownership by 0.51% to 3,616,715 units (SEC Form 4)

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    3/20/24 5:22:00 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Papadopoulos Stelios

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    4/9/26 5:15:09 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fitzgerald Kevin Joseph

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    4/9/26 5:15:06 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Friedman Bart

    4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

    4/9/26 5:15:07 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ovid Therapeutics to Participate in Upcoming Investor Conferences

    NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in two upcoming investor conferences: Oppenheimer CNS & Neuro-Muscular Summit – Wednesday, June 10 at 3:45 pm ETH.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference – Monday, June 15 A webcast of the presentations can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the

    6/4/26 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

    NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced the appointment of Anna Greka, M.D., Ph.D., to its Board of Directors, effective June 15, 2026. "Anna is a visionary, passionate physician-scientist and entrepreneur whose work sits at the intersection of groundbreaking nodal biology and therapeutic innovation," said Meg Alexander, President and Chief Executive Officer, Ovid Therapeutics. "Her pioneering work in ion channel biology has fundamentally advanced our understanding of disease biology and enabled the develop

    6/3/26 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

    Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteersOV329 showed favorable safety, tolerability, pharmacokinetics (PK), and drug exposure at higher doses, supporting the planned advancement of Phase 2 and proof-of-concept studiesAnnounced development expansion of OV329 into additional pediatric indications of tuberous sclerosis complex (TSC) seizures and infantile spasms (IS), conditions for which GABA-aminotransferase (GABA-AT) inhibition is a validated mechanismStrengthened balance sheet, raising $60.0 million of gross proceeds in March 2026 PIPE financing with participati

    5/12/26 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Leadership Updates

    Live Leadership Updates

    View All

    Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors

    NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced the appointment of Anna Greka, M.D., Ph.D., to its Board of Directors, effective June 15, 2026. "Anna is a visionary, passionate physician-scientist and entrepreneur whose work sits at the intersection of groundbreaking nodal biology and therapeutic innovation," said Meg Alexander, President and Chief Executive Officer, Ovid Therapeutics. "Her pioneering work in ion channel biology has fundamentally advanced our understanding of disease biology and enabled the develop

    6/3/26 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

    NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid's leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance. Dr. Kaufmann brings extensive experience developing CNS therapeutics from first-in-human studies through to global regula

    12/2/25 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

    NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

    3/3/25 8:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

    SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    11/14/24 6:01:44 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

    SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    11/14/24 4:39:42 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

    SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

    2/14/24 4:15:31 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OVID
    Financials

    Live finance-specific insights

    View All

    Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

    An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor, vigabatrin (VGB), as measured on transcranial magnetic stimulation (TMS) 1Findings confirm OV329 penetrates the brain, engages the target and achieves biological modulation as expected of elevated levels of GABA, the major inhibitory neurotransmitterSafety and tolerability results are supportive of further development and appear to be preferable relative to marketed anti-seizure medicines (ASMs)Ovid plans to advance OV329 into a Phase 2a study in d

    10/3/25 7:00:00 AM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand Reports Second Quarter 2024 Financial Results

    Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

    8/6/24 4:01:00 PM ET
    $AGEN
    $AMGN
    $CASI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations